Compared side by side

Semaglutide vs petrelintide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

They act on different hormones: semaglutide is a GLP-1 receptor agonist, and petrelintide, from Zealand Pharma and Roche, is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin, designed to stay stable so it can be mixed with other peptides. Semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy; petrelintide has been in phase 3 since September 2026 and isn’t approved anywhere. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial, and petrelintide up to about 10.7% by week 42 in phase 2, with GI side effects close to placebo apart from mild nausea.

Side by side

ComparedSemaglutidePetrelintide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asOzempic, WegovyZP8396, Petre
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.A once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin.
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.Long-acting analogue of human amylin, the fullness hormone the pancreas releases with insulin. Amylin receptor activation is thought to make the body more responsive to leptin, its satiety signal, so people feel full sooner. A fatty-acid chain binds it to albumin in the blood, giving a half-life of about 10 days. Zealand designed it to stay stable at neutral pH so it can be mixed with other peptides, and Roche is testing it with its own GLP-1 drug. Investigational, in phase 3 since September 2026.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.Feeling full sooner and smaller portions. It is in phase 3 and not approved anywhere.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.Research range: 1–9 mg, starting dose 0.6 mg. Studied in research — not a recommendation.
How oftenWeekly SubQWeekly
Half-life~1 week (FDA label)~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.Used continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskNausea, decreased appetite, constipation, diarrhea

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or petrelintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Petrelintide

  • Day 1–28 Fullness, gently
  • Day 29–294 · 2.5 mg Low doses already work
  • Day 57–294 · 5 mg Five milligrams
  • Day 85–294 · 9 mg The top dose tested
  • Day 85–294 With type 2 diabetes
  • Day 197–294 Weeks 28 to 42: still moving

Every card for petrelintide, with its sources

Together or one or the other

Semaglutide and petrelintide are a common stack: petrelintide lists semaglutide among its common stacks.

Community · Petrelintide

Petrelintide beside a GLP-1

Amylin and GLP-1 drugs work on appetite in different ways, which is why CagriSema pairs them. Roche plans a trial of petrelintide with its own GLP-1/GIP drug. Commonly reported: the pair adds fullness, and GI side effects add up too. No published trial has tested petrelintide with a GLP-1 yet.

Questions people ask

How long do semaglutide and petrelintide last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of petrelintide is ~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026).

How often are semaglutide and petrelintide taken?

Semaglutide: weekly SubQ. Route: SubQ injection. Petrelintide: weekly. Route: SubQ injection.

How are semaglutide and petrelintide dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for petrelintide is 1–9 mg, with a 0.6 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of semaglutide and petrelintide?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For petrelintide: nausea, decreased appetite, constipation, diarrhea.

Are semaglutide and petrelintide taken together?

Semaglutide and petrelintide are a common stack: petrelintide lists semaglutide among its common stacks. Amylin and GLP-1 drugs work on appetite in different ways, which is why CagriSema pairs them. Roche plans a trial of petrelintide with its own GLP-1/GIP drug. Commonly reported: the pair adds fullness, and GI side effects add up too. No published trial has tested petrelintide with a GLP-1 yet.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or petrelintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo